Research into Bosutinib
Early Phase II Results Show Bosutinib Safe, Effective for CML - Press release from MD Anderson
Targeted therapy in chronic myeloid leukemia. - MD Anderson overview
Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors - abstract from Nature
Bosutinib (SKI-606), a dual Src/Abl tyrosine kinase inhibitor: Preliminary results from a phase 1 study in patients with advanced malignant solid tumors. - abstract from American Society of Clinical Oncology annual meeting in 2007. Concluded that bosutinib was well tolerated.
Tailoring tyrosine kinase inhibitor therapy to tackle specific BCR-ABL1 mutant clones - mentions several TKIs under development for CLL patients.
SKI-606 (bosutinib), a novel Src kinase inhibitor, suppresses migration and invasion of human breast cancer cells - Wyeth Research paper abstract